Clinical trial
A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure
NCT04298229 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure
- Lead sponsor
- Vanderbilt University Medical Center
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 1, 2020
- Completion date
- May 17, 2023
- Enrollment
- 240 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.